

By revenue, UnitedHealth Group is the nation's largest publicly traded managed care company. It operates through two business segments, UnitedHealthcare and Optum. UnitedHealthcare provides healthcare benefits through four membership groups: Employers & Individual, Medicare & Retirement, Community & State, and International. Optum segment is a health services business that serves payers, care providers, employers, governments, life science companies, and consumers.

Analyst's Notes

Analysis by David Tounge, May 14, 2025

ARGUS RATING: HOLD

- Cloudy growth outlook amid rising medical costs
- Given UNH's suspension of guidance for 2025, we see an uncertain near-term outlook for the company's earnings. Still, should we see evidence of a return to profitable growth from UNH, we would consider an upgrade to the BUY list.
- Stephen Hemsley has been appointed CEO, succeeding Andrew Witty, who stepped down for personal reasons.
- We are reducing our estimates for adjusted EPS to \$26.00 from \$26.25 for 2025 and to \$28.50 from \$31.00 for 2026.

INVESTMENT THESIS

For HOLD-rated UnitedHealth Group Inc. (NYSE: UNH), the dynamics of navigating the post-pandemic environment has been challenging. Patients have returned to elective procedures. Medical utilization, including physician office visits and outpatient care, remain elevated, putting pressure on the medical cost ratio and reducing profit margins.

On the other hand, the demographics of an aging population remain a favorable tailwind, as the increasing population of older Americans will need health benefit plans and services to manage their healthcare needs.


Still, should we see evidence of a return to profitable growth from UNH, we would consider an upgrade to the BUY list.

RECENT DEVELOPMENTS

The unexpected departure of Andrew Witty as CEO, along with the suspension of 2025 guidance, gives us less confidence in the growth strategy of the company. Stephen Hemsley, who succeeds Witty as CEO, is a known quantity as he had a solid track record of success in his prior tenure as CEO in 2006-2017. CEO succession aside, we are concerned about rising medical utilization and costs in the Medicare Advantage business. In fact, the company said the unexpected rise in utilization has now extended to other insurance

Market Data Pricing reflects previous trading week's closing price.

— 200-Day Moving Average ● 52 Week High: \$595.63 ○ 52 Week Low: \$307.11 ● Closed at \$380.64 on 5/9



| Rating | | BUY HOLD SELL | | | |
|----------------------|---|---------------------|--|--|--|
| EPS (\$) | | | | | |
| Quarterly | 6.26 6.14 6.56 6.24 6.91 6.80 7.15 6.81 7.20 6.00 6.35 6.45 7.70 7.00 7.00 6.80 | | | | |
| Annual | 25.12 27.66 26.00 (Estimate) 28.50 (Estimate) | | | | |
| Revenue (\$ in Bil.) | | | | | |
| Quarterly | 91.9 92.9 92.4 94.4 99.8 98.9 100.8 100.8 109.6 107.8 109.9 109.9 119.4 117.5 119.8 119.8 | | | | |
| Annual | 371.6 400.3 437.1 (Estimate) 476.5 (Estimate) | | | | |
| FY ends Dec 31 | Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 | | | | |
| | 2023 2024 2025 2026 | | | | |

Argus Recommendations

| | | | |
|---------------------|--------------|---------------|-------------|
| Twelve Month Rating | SELL | HOLD | BUY |
| Five Year Rating | SELL | HOLD | BUY |
| Sector Rating | Under Weight | Market Weight | Over Weight |

Argus assigns a 12-month BUY, HOLD, or SELL rating to each stock under coverage.

- BUY-rated stocks are expected to outperform the market (the benchmark S&P 500 Index) on a risk-adjusted basis over the next year.
- HOLD-rated stocks are expected to perform in line with the market.
- SELL-rated stocks are expected to underperform the market on a risk-adjusted basis.

The distribution of ratings across Argus' entire company universe is: 73% Buy, 27% Hold, 0% Sell.

Key Statistics

Key Statistics pricing data reflects previous trading day's closing price. Other applicable data are trailing 12-months unless otherwise specified

Market Overview

| | |
|---------------------|----------------------|
| Price | \$308.01 |
| Target Price | -- |
| 52 Week Price Range | \$307.11 to \$630.73 |
| Shares Outstanding | 907.14 Million |
| Dividend | \$8.40 |

Sector Overview

| | |
|--------------------------------|-------------|
| Sector | Healthcare |
| Sector Rating | OVER WEIGHT |
| Total % of S&P 500 Market Cap. | 10.80% |

Financial Strength

| | |
|---------------------------|------------------|
| Financial Strength Rating | MEDIUM-HIGH |
| Debt/Capital Ratio | 44.4% |
| Return on Equity | 25.1% |
| Net Margin | 5.4% |
| Payout Ratio | 0.32 |
| Current Ratio | 0.83 |
| Revenue | \$410.06 Billion |
| After-Tax Income | \$22.11 Billion |

Valuation

| | |
|-----------------------|------------------|
| Current FY P/E | 11.85 |
| Prior FY P/E | 11.14 |
| Price/Sales | 0.68 |
| Price/Book | 2.95 |
| Book Value/Share | \$104.44 |
| Market Capitalization | \$279.41 Billion |

Forecasted Growth

| | |
|---------------------------------|--------|
| 1 Year EPS Growth Forecast | -6.00% |
| 5 Year EPS Growth Forecast | 11.00% |
| 1 Year Dividend Growth Forecast | 0% |

Risk

| | |
|-------------------------|--------|
| Beta | 0.40 |
| Institutional Ownership | 89.66% |

Analyst's Notes ...Continued

sectors beyond Medicare Advantage.

This elevated medical utilization is clearly pressuring the profit margins of the UnitedHealthcare insurance business. Management said the 'care activity continued to accelerate while also broadening to more types of benefit offerings than seen in the first quarter.' This elevated utilization indicates that UNH's members have increased their physician office visits and are undergoing more outpatient procedures.

Since we view this suspension of guidance, in the backdrop of rising medical costs, as essentially a cut in guidance, this marks the second time in less than a month that UNH had lowered its 2025 outlook. It had cut guidance when it reported 1Q25 results on April 17.

UNH also said it would appropriately set pricing for and adjust its insurance plan offerings in order to return to its long-term target margin range of 3%-5%. It will incorporate the higher utilization experiences and expectations into its 2026 Medicare Advantage bids that are due in a few weeks. UNH said it expects to return to growth in 2026.

EARNINGS & GROWTH ANALYSIS

Based on UNH's guidance suspension for 2025 and management's comments regarding rising medical utilization, we are reducing our estimates for adjusted EPS. We are reducing our estimate to \$26.00 from \$26.25 for 2025 and to \$28.50 from \$31.00 for 2026.

FINANCIAL STRENGTH & DIVIDEND

Our financial strength rating on UNH is Medium-High, the second-highest rank on our five-point scale. The company has a solid balance sheet and strong cash flow. Cash flow from operations was \$24.2 billion for 2024, compared to \$29.1 billion in the year-ago period.

UNH pays a dividend at the annualized rate of \$8.40 for a current yield of 2.7%. With its 11% dividend raise earlier in 2024, the company marked 15 consecutive years of dividend hikes. Our dividend estimates are \$8.40 (reduced from \$9.00) for 2025 and \$9.00 (reduced from \$9.60) for 2026.

MANAGEMENT AND RISKS

As noted earlier, Stephen Hemsley was appointed CEO, succeeding Andrew Witty, who had served as CEO from 2021 until May 2025.

John Rex is president and CFO.

UnitedHealth faces competitive risks in both the commercial and government-sponsored markets as rival insurers, both for-profit and not-for-profit, seek to expand share. It also faces actuarial risks, as it must estimate the growth of healthcare costs and the use of medical services by its members. The profit margin of the UnitedHealthcare insurance segment is measured by the medical cost ratio (MCR), which is the ratio of medical costs to premium revenue. A lower ratio means a higher profit margin.

The company also faces legal risks as its acquisitions face

Growth & Valuation Analysis

GROWTH ANALYSIS

(\$ in Millions, except per share data)

| | 2020 | 2021 | 2022 | 2023 | 2024 |
|----------------------------|---------|---------|---------|---------|---------|
| Revenue | 257,141 | 287,597 | 324,162 | 371,622 | 400,278 |
| COGS | 190,141 | 217,945 | 244,545 | 280,664 | 310,879 |
| Gross Profit | 67,000 | 69,652 | 79,617 | 90,958 | 89,399 |
| SG&A | — | — | — | — | — |
| R&D | — | — | — | — | — |
| Operating Income | 22,405 | 23,970 | 28,435 | 32,358 | 32,287 |
| Interest Expense | 1,663 | 1,660 | 2,092 | 3,246 | 3,906 |
| Pretax Income | 20,742 | 22,310 | 26,343 | 29,112 | 20,071 |
| Income Taxes | 4,973 | 4,578 | 5,704 | 5,968 | 4,829 |
| Tax Rate (%) | 24 | 21 | 22 | 21 | 24 |
| Net Income | 15,403 | 17,285 | 20,120 | 22,381 | 14,405 |
| Diluted Shares Outstanding | 961 | 956 | 950 | 938 | 929 |
| EPS | 16.03 | 18.08 | 21.18 | 23.86 | 15.51 |
| Dividend | 4.83 | 5.60 | 6.40 | 7.29 | 8.18 |

GROWTH RATES (%)

| | | | | | |
|-------------------------|------|------|------|------|-------|
| Revenue | 6.2 | 11.8 | 12.7 | 14.6 | 7.7 |
| Operating Income | 13.8 | 7.0 | 18.6 | 13.8 | -0.2 |
| Net Income | 11.3 | 12.2 | 16.4 | 11.2 | -35.6 |
| EPS | 11.9 | 12.8 | 17.1 | 12.7 | -35.0 |
| Dividend | 16.7 | 15.9 | 14.3 | 13.9 | 12.2 |
| Sustainable Growth Rate | 20.4 | 15.1 | 18.7 | 18.9 | 7.7 |

VALUATION ANALYSIS

| | | | | | |
|---------------------------|-------------|-------------|-------------|-------------|-------------|
| Price: High | \$367.95 | \$509.23 | \$558.10 | \$554.70 | \$630.73 |
| Price: Low | \$187.72 | \$320.35 | \$445.74 | \$445.68 | \$436.38 |
| Price/Sales: High-Low | 1.4 - 0.7 | 1.7 - 1.1 | 1.6 - 1.3 | 1.4 - 1.1 | 1.5 - 1.0 |
| P/E: High-Low | 23.0 - 11.7 | 28.2 - 17.7 | 26.4 - 21.0 | 23.2 - 18.7 | 40.7 - 28.1 |
| Price/Cash Flow: High-Low | 15.9 - 8.1 | 19.3 - 12.2 | 15.7 - 12.5 | 17.6 - 14.1 | 35.3 - 24.4 |

Financial & Risk Analysis

FINANCIAL STRENGTH

| | 2022 | 2023 | 2024 |
|----------------------------------|---------|---------|---------|
| Cash (\$ in Millions) | 23,365 | 25,427 | 25,312 |
| Working Capital (\$ in Millions) | -20,168 | -20,617 | -17,990 |
| Current Ratio | 0.77 | 0.79 | 0.83 |
| LT Debt/Equity Ratio (%) | 70.1 | 65.6 | 78.1 |
| Total Debt/Equity Ratio (%) | 74.1 | 70.5 | 83.0 |

RATIOS (%)

| | | | |
|---------------------|------|------|------|
| Gross Profit Margin | 24.6 | 24.5 | 22.3 |
| Operating Margin | 8.8 | 8.7 | 8.1 |
| Net Margin | 6.2 | 6.0 | 3.6 |
| Return On Assets | 8.8 | 8.6 | 5.0 |
| Return On Equity | 26.9 | 26.9 | 15.9 |

RISK ANALYSIS

| | | | |
|--------------------------------|------|------|------|
| Cash Cycle (days) | — | — | — |
| Cash Flow/Cap Ex | 9.4 | 8.6 | 6.9 |
| Oper. Income/Int. Exp. (ratio) | 13.6 | 10.0 | 6.1 |
| Payout Ratio | 33.5 | 30.4 | 30.6 |

Analyst's Notes ...Continued

regulatory scrutiny. The acquisition of Change Healthcare had a protracted regulatory review that ultimately forced UNH to divest certain Change businesses before completing the acquisition.

COMPANY DESCRIPTION

By revenue, UnitedHealth Group is the nation's largest publicly traded managed care company. It operates through two business segments, UnitedHealthcare and Optum. UnitedHealthcare provides healthcare benefits through four membership groups: Employers & Individual, Medicare & Retirement, Community & State, and International. Optum segment is a health services business that serves payers, care providers, employers, governments, life science companies, and consumers.

The Optum Health business provides care delivery in primary and specialty care, care management, wellness programs, and offers consumer engagement services. OptumInsight uses advanced data analytics and technology to help optimize the performance of clients. OptumRx provides pharmacy benefit management services (PBM).

VALUATION


UNH is trading at 10.9-times our 2026 EPS estimate, below the mean of 12.6 for our coverage universe of managed care stocks.

On May 14, HOLD-rated UNH closed at 308.01, down \$3.37.

Peer & Industry Analysis


The graphics in this section are designed to allow investors to compare UNH versus its industry peers, the broader sector, and the market as a whole, as defined by the Argus Universe of Coverage.

- The scatterplot shows how UNH stacks up versus its peers on two key characteristics: long-term growth and value. In general, companies in the lower left-hand corner are more value-oriented, while those in the upper right-hand corner are more growth-oriented.
- The table builds on the scatterplot by displaying more financial information.
- The bar charts on the right take the analysis two steps further, by broadening the comparison groups into the sector level and the market as a whole. This tool is designed to help investors understand how UNH might fit into or modify a diversified portfolio.




| Ticker | Company | Market Cap (\$ in Millions) | 5-yr Growth Rate (%) | Current FY P/E | Net Margin (%) | 1-yr EPS Growth (%) | Argus Rating |
|--------------|------------------------|--------------------------------|----------------------------|-------------------|----------------------|---------------------------|-----------------|
| UNH | Unitedhealth Group Inc | 279,408 | 11.0 | 11.8 | 5.4 | 9.6 | HOLD |
| ISRG | Intuitive Surgical Inc | 202,843 | 12.0 | 73.0 | 28.4 | 16.1 | BUY |
| HCA | HCA Healthcare Inc | 88,411 | 10.0 | 14.8 | 8.1 | 12.3 | BUY |
| MCK | Mckesson Corporation | 85,362 | 9.0 | 20.8 | .9 | 12.1 | BUY |
| ELV | Elevance Health Inc | 84,565 | 9.0 | 10.4 | 3.2 | 7.1 | BUY |
| CVS | CVS Health Corp | 75,952 | 15.0 | 9.8 | 1.4 | 14.2 | BUY |
| COR | Cencora Inc | 54,106 | 10.0 | 18.1 | .5 | 8.4 | BUY |
| CAH | Cardinal Health, Inc. | 35,422 | 10.0 | 18.3 | .7 | 11.9 | BUY |
| Peer Average | | 113,259 | 10.8 | 22.1 | 6.1 | 11.5 | |


P/E




Price/Sales




Price/Book




PEG



5 Year Growth



Debt/Capital



About Argus

Argus Research, founded by Economist Harold Dorsey in 1934, has built a top-down, fundamental system that is used by Argus analysts. This six-point system includes Industry Analysis, Growth Analysis, Financial Strength Analysis, Management Assessment, Risk Analysis and Valuation Analysis.

Utilizing forecasts from Argus' Economist, the Industry Analysis identifies industries expected to perform well over the next one-to-two years.

The Growth Analysis generates proprietary estimates for companies under coverage.

In the Financial Strength Analysis, analysts study ratios to understand profitability, liquidity and capital structure.

During the Management Assessment, analysts meet with and familiarize themselves with the processes of corporate management teams.

Quantitative trends and qualitative threats are assessed under the Risk Analysis.

And finally, Argus' Valuation Analysis model integrates a historical ratio matrix, discounted cash flow modeling, and peer comparison.

THE ARGUS RESEARCH RATING SYSTEM

Argus uses three ratings for stocks: BUY, HOLD, and SELL. Stocks are rated relative to a benchmark, the S&P 500.

- A BUY-rated stock is expected to outperform the S&P 500 on a risk-adjusted basis over a 12-month period. To make this determination, Argus Analysts set target prices, use beta as the measure of risk, and compare expected risk-adjusted stock returns to the S&P 500 forecasts set by the Argus Market Strategist.
- A HOLD-rated stock is expected to perform in line with the S&P 500.
- A SELL-rated stock is expected to underperform the S&P 500.

Argus Research Disclaimer

Argus Research Co. (ARC) is an independent investment research provider whose parent company, Argus Investors' Counsel, Inc. (AIC), is registered with the U.S. Securities and Exchange Commission. Argus Investors' Counsel is a subsidiary of The Argus Research Group, Inc. Neither The Argus Research Group nor any affiliate is a member of the FINRA or the SIPC. Argus Research is not a registered broker dealer and does not have investment banking operations. The Argus trademark, service mark and logo are the intellectual property of The Argus Research Group, Inc. The information contained in this research report is produced and copyrighted by Argus Research Co., and any unauthorized use, duplication, redistribution or disclosure is prohibited by law and can result in prosecution. The content of this report may be derived from Argus research reports, notes, or analyses. The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Argus Research makes no representation as to their timeliness, accuracy or completeness or for their fitness for any particular purpose. The historical Growth & Valuation and Financial & Risk financial information included in this report has been provided by Morningstar, Inc. (© Morningstar, Inc. All Rights Reserved). This data is proprietary to Morningstar and/or its content providers; may not be copied or distributed; is not warranted to be accurate, complete or timely; and is set forth herein for historical reference only and is not necessarily used in Argus' analysis of the stock set forth in the pages of this report or any other stock or other security. This report is not an offer to sell or a solicitation of an offer to buy any security. The information and material presented in this report are for general information only and do not specifically address individual investment objectives, financial situations or the particular needs of any specific person who may receive this report. Investing in any security or investment strategies discussed may not be suitable for you and it is recommended that you consult an independent investment advisor. Nothing in this report constitutes individual investment, legal or tax advice. Argus Research may issue or may have issued other reports that are inconsistent with or may reach different conclusions than those represented in this report, and all opinions are reflective of judgments made on the original date of publication. Argus is under no obligation to ensure that other reports are brought to the attention of any recipient of this report. Argus and its content providers shall accept no liability for any loss arising from the use of this report, nor shall Argus treat all recipients of this report as customers simply by virtue of their receipt of this material. Investments involve risk and an investor may incur either profits or losses. Past performance should not be taken as an indication or guarantee of future performance. Argus has provided independent research since 1934. Argus officers, employees, agents and/or affiliates may have positions in stocks discussed in this report. No Argus officers, employees, agents and/or affiliates may serve as officers or directors of covered companies, or may own more than one percent of a covered company's stock. AIC is a customer of ARC. AIC pays ARC for research used in the management of the AIC core equity strategy and model portfolio and unit investment trust products, and has the same access to ARC content as other customers. However, clients and prospective clients should note that AIC and ARC, as units of The Argus Research Group, have certain employees in common, including those with both research and portfolio management responsibilities, and that ARC employees participate in the management and marketing of the AIC core equity strategy and UIT and model portfolio products. Recipients of the Research reports in Singapore should contact the Intermediary of the Research Reports in respect to any matters arising from, or in connection with, the analysis of the report. When reports are distributed by Intermediaries in Singapore, the Intermediary, and not Argus Research, is solely responsible for ensuring that the recipients of the Research Reports are accredited, expert or institutional investors as defined by the Securities and Futures Act. The Intermediary is also solely responsible for ensuring that the recipients understand the information contained in the Research Reports and that such information is suitable based on the recipient's profile and investment objectives. Laws and regulations of other countries may also restrict the distribution of this report. Persons in possession of this document should inform themselves about possible legal restrictions and observe them accordingly. This content is not prepared subject to Canadian disclosure requirements.